Tyra biosciences receives fda rare pediatric disease designation for tyra-300 for the treatment of achondroplasia

Carlsbad, calif. , feb. 1, 2024 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today announced that the u.s. food and drug administration (fda) has granted rare pediatric disease (rpd) designation to tyra-300, an oral fgfr3 selective inhibitor, for the treatment of achondroplasia.
TYRA Ratings Summary
TYRA Quant Ranking